US · Healthcare · Biotechnology
EPS came in at 0.02 against a street estimate of 0.08 — a miss of 75.0%.
Analysts rate ACADIA Pharmaceuticals Inc a buy (13 buy, 6 hold, 1 sell out of 20) with an average price target of $32.95.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 25.05% |
| BlackRock Inc | 12.59% |
| Vanguard Portfolio Management, LLC | 5.06% |
| State Street Corp | 4.87% |
| RTW INVESTMENTS, LLC | 4.17% |
| Vanguard Capital Management, LLC | 3.31% |
| Geode Capital Management, LLC | 2.02% |
| First Trust Advisors L.P. | 1.95% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-05-29 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-06 |
| Board / officer change · Q2 2026 | 2026-05-01 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Board / officer change · Q1 2026 | 2026-03-05 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ACADIA Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.